Long‐Term Azithromycin Therapy in Cystic Fibrosis Patients: A Study on Drug Levels and Sputum Properties | Zendy

Ulrich Baumann | Zendy; Malcolm King | Zendy; Ernst M. App | Zendy; Shusheng Tai | Zendy; Armin König | Zendy; Julia J Fischer | Zendy; Torsten Zimmermann | Zendy; Wolfgang Sextro | Zendy; H. von der Hardt | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Long‐Term Azithromycin Therapy in Cystic Fibrosis Patients: A Study on Drug Levels and Sputum Properties

Author(s) -

Ulrich Baumann,

Malcolm King,

Ernst M. App,

Shusheng Tai,

Armin König,

Julia J Fischer,

Torsten Zimmermann,

Wolfgang Sextro,

H. von der Hardt

Publication year - 2004

Publication title -

canadian respiratory journal

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.675

H-Index - 53

eISSN - 1916-7245

pISSN - 1198-2241

DOI - 10.1155/2004/747841

Subject(s) - medicine , azithromycin , cystic fibrosis , sputum , pharmacotherapy , drug , intensive care medicine , term (time) , antibiotics , tuberculosis , pharmacology , pathology , microbiology and biotechnology , biology , physics , quantum mechanics

Following reports on the treatment of diffuse panbronchiolitis (DPB), recent studies demonstrate that long term therapy with azithromycin (AZM) is effective in cystic fibrosis (CF) patients. However, the underlying mechanisms remain uncertain. Some macrolides, including AZM, display inhibition of virulence factors and other antipseudomonal effects at subinhibitory levels in vitro.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research